Functional PDGFa receptors are selectively expressed on highly lung-metastasizing clones of the 3LL Lewis lung carcinoma, but not on low-mestastatic clones. The highly metastatic clones are also growth induced in vitro by PDGF and lung conditioned medium. To investigate whether modi®cation of PDGFa receptor expression or function can aect metastatic capability, we transfected cells of a low-metastatic 3LL clone with a full length PDGFa receptor gene and cells of a highly-metastatic clone with a truncated kinase domain PDGFa receptor gene. Introduction of the full length PDGFa receptor conferred upon low-metastatic cells the ability to grow in vitro in the presence of PDGF-AA and to colonize the lung in experimental and spontaneous metastases assays. Conversely, introduction of a truncated version of the PDGFa receptor into highly metastatic cells reduced their metastatic load to control levels. Accordingly, their responses to PDGF-AA, including growth stimulation and receptor autophosphorylation, were reduced. These results demonstrate that PDGFa receptor expression and function can control the capacity of tumor cells to generate metastases in the lung. The response of this receptor to lung-derived PDGF-like factors may de®ne a paracrine mode of metastatic cell growth in the target organ.
Introduction
Metastasis is de®ned as the spread of cells from a primary neoplasm to distant secondary sites and proliferation at these sites. As early as 1889, Paget proposed that the growth of metastasis is due to the speci®c interaction of tumor cells with particular organ environments (Paget, 1889) . This hypothesis has been supported both experimentally and clinically (Hart et al., 1981; Tarin et al., 1984) . Multiple cellular properties are involved in the ability of tumor cells to colonize distant organ. These include adhesion to tissue speci®c endothelial cells, invasion into extracellular matrices, escape from local host immune factors, and response to tissue speci®c chemotactic and mitogenic signals (Fidler, 1989) . Thus signals from the microenvironment of a target organ can in¯uence the survival and growth of invading tumor cells, equipped with appropriate receptors (Fidler, 1990; Radinsky and Fidler, 1992; Rusciano and Burger, 1992) .
The receptor tyrosine kinases (RTK's) mediate cellular growth, dierentiation, and metabolic activities. The PDGF receptor, a member of the third subclasses of RTK's, is actually composed of two separate polypeptide chains, a and b, diering in their ligand speci®city Heldin et al., 1988a) . The a receptor recognizes with high anity all three isoforms of PDGF whereas the b receptor binds PDGF-BB with high anity and PDGF-AB with lower anity but does not bind PDGF-AA (Heldin et al., 1988a) . The cDNAs encoding a and b receptors of PDGF have been cloned and sequenced, and their primary structures have been shown to be structurally similar (Claesson-Welsh et al., 1988 Do et al., 1992; Gronwald et al., 1988; Lee et al., 1990; Matsui et al., 1989; Yarden et al., 1986) . The PDGF receptors, once thought to be restricted to anchorage-dependent cells of mesenchymal lineages such as ®broblasts, chondroblasts, and glial cells, have now been found in a variety of malignant tumor cells and numerous tumor cell lines (Do et al., 1992; FitzerAttas et al., 1993; Harsh et al., 1990; Heldin et al., 1988b; Iida et al., 1991; Leveen et al., 1990; Malik et al., 1991; Maxwell et al., 1990a, b; Wang et al., 1990) . In fact, the role of PDGF in tumorigenesis is inferred by the strong homology between PDGF-B and p28 v-sis , the transforming protein of simian sarcoma virus. Both these genes are highly transforming when expressed at high levels in murine ®broblasts (Deuel, 1987) .
We have isolated, by limiting dilution, high-and lowmetastatic clones from the parental 3LL murine tumor; the high-metastatic clones metastasize exclusively to the lungs (DeBaetselier et al., 1980; Eisenbach et al., 1983 ). An earlier report of ours showed that the PDGFa receptor is preferentially expressed in high-metastatic but not in low-metastatic 3LL clones (Do et al., 1992) . Detailed biochemical comparison of 3LL high (D122) and low (A9) metastatic clones revealed that this receptor is functional, able to respond to short-and long-term exposure to PDGF . These high-metastatic cells, which metastasize specifically to the lungs, are growth induced in vitro by PDGF-AA and -BB as well as by lung conditioned media to a greater extent than are low-metastatic cells. Moreover, lung conditioned, in contrast to kidney or liver conditioned media, is highly enriched in PDGFlike ligands .
To investigate whether modi®cations of the expression or function of PDGFa receptors can alter the metastatic phenotype, we have overexpressed the PDGFa receptor in low-metastatic 3LL clone and introduced a dominant negative PDGFa receptor into a high-metastatic clone. These modi®cations significantly changed the metastatic phenotype of the original clone, suggesting that signaling through PDGFa receptors directly aects the growth of metastases in the lung.
Results

Overexpression of the wild-type PDGFa receptor in low metastatic cells
To investigate if the overexpression of PDGFa receptors can confer a lung-seeking metastatic phenotype, a 3.5 kbp cDNA insert containing the entire 1089 amino acids long open reading frame of the mouse PDGFa receptor was inserted into the SmaI site of the pSVL mammalian expression vector and cotransfected with pSV2neo into low metastatic A9 cells. Selection in geneticin yielded 24 resistant clones. Mock transfections were performed with pSV2neo and the pSVL vector lacking an insert. Cloned transfectants were tested for expression of PDGFa receptor by Northern blot analysis with a PDGFa receptor speci®c 1.8 kb HindIII ± BamHI cDNA probe. Hybridization to RNA from the high-metastatic, PDGFa receptorexpressor clone D122 and from the low-metastatic, non-expressor clone A9 was performed for comparison. While clone A9 and mock transfectants AP1 and AP3 do not express PDGFa receptor related mRNA, clone D122 and ®ve of the transfected clones (AN20, AN22, AN23, AN23-1, AN24) showed high to moderate steady-state levels of PDGFa receptor speci®c antibody R5 . Immunoblots revealed 185 kDa and 170 kDa proteins, representing mature and immature forms of the PDGFa receptor, speci®cally recognized at high to moderate levels in lysates of transfected clones and D122 cells (Figure 1b) . Lysates from low metastatic A9 and mock transfected clones AP1 and AP3 contained little or no receptor protein (Figure 1b) . Expression of PDGFa receptor RNA and protein levels were well correlated amongst the dierent clones.
Expression of a truncated PDGF-a receptor in high metastatic cells
Overexpression of tyrosine kinase-mutated PDGF receptors has been shown to cause the formation of inactive receptor heterodimers, unable to autophosphorylate or signal to the cell's interior (Kemp et al., 1993; Strawn et al., 1994; Ueno et al., 1991 Ueno et al., , 1993 . We therefore postulated that expression of a dominant negative PDGFa receptor in high metastatic D122 cells might diminish or abolish the function of endogenous PDGFa receptors and lead to downregulation of the metastatic phenotype. A kinase mutant PDGFa receptor was prepared by site-directed mutagenesis, introducing a stop codon at tyrosine 572 within the juxtamembrane domain. Once cloned into a Rc/CMV expression vector, the mutated PDGFa receptor was transfected into the high metastatic clone D122, which express high levels of wild-type PDGFa receptors. Mock transfections were performed with an empty Rc/ CMV vector. RNA from geneticin-resistant clones were screened by Northern blot analysis for the presence of truncated receptor, using a 1.8 kb PDGFa receptor extracellular and transmembrane domain probe ( Figure  2a ). While D122 and mock transfectants (CMV-S7 and CMV-S8) express only the wild-type 6.5 kb PDGFa receptor transcript, clones MD4, MD5, and MD10 express both endogenous and truncated RNA species. Within each transfectant, the levels of wild-type and mutant RNA were similar. MD11 is a G418-resistant clone which does not express detectable levels of the mutant receptor. Transfectants were also assayed for the presence of full length endogenous and truncated receptor by Western blotting with a polyclonal antibody to the extracellular region of the PDGFa receptor (Hall et al., 1996) . Immunoblots revealed the expected 64 kDa protein, corresponding to the molecular weight of the 572 amino acid kinase-mutant receptor. A series of higher molecular weight bands may represent dierentially glycosylated or other disul®de-linked species (Figure 2b ). Of course, both the truncated receptor transfectants (MD4 and MD5) and the mock transfectants (CMV-S7 and CMV-S8) express the full-length endogenous receptor as well (Figure 2b ).
To test if the kinase mutant PDGFa receptor indeed functions in a dominant negative fashion, we examined the ability of endogenous receptors to autophosphorylate in response to PDGF, the ®rst step of their signaling cascade (Claesson-Welsh, 1994) . To this end, mock-transfected CMV-S8 cells and 2 clones expressing the mutant receptor (MD4 and MD5) were placed in serum-free media overnight and then stimulated with PDGF-AA for 10 min. Cells were lysed and wild-type PDGFa receptors immunoprecipitated with antibodies that recognize C-terminal sequences. Immunoblotting with anti-phosphotyrosine antibodies revealed strong autophosphorylation of the PDGFa receptor in mocktransfected cells, which was greatly reduced in both MD4 and MD5 clones which contain the kinase mutant receptor (Figure 2c ). The same cell lysates, however, when immunoblotted with anti-PDGFa receptor antibodies showed similar levels of endogenous receptor (Figure 2d ).
PDGFa receptor modi®cations aect the PDGF-induced growth of transfected cells
Ligand binding to PDGF receptors will often result in increased proliferation of responding cells (Westermark and Heldin, 1993; Williams, 1989) . This may be a crucial event for the growth of invading tumor cells in a foreign organ environment providing PDGF signals. Thus the proliferation of PDGFa receptor-modi®ed cells in response to PDGF was measured in a 4 day growth assay. As can be seen in Figure 3a , cells which overexpress wild-type PDGFa receptors (AN20, AN22, AN23, AN23-1 and AN24) grow more rapidly in response to increasing concentrations of PDGF-AA than do low metastatic parental (A9) or mocktransfected (AP1 and AP3) cells. However, most clones still grew at rates slower than high metastatic D122 cells. One exception is the clone AN23-1, a cell line recultured from a metastatic nodule of the clone AN23, which was stimulated to grow in the presence of PDGF-AA at levels similar to D122 cells.
Conversely, cells expressing the kinase mutant PDGFa receptor (MD4, MD5 and MD10) show a decrease of almost 100% in growth stimulation by PDGF-AA containing media when compared to parental high metastatic (D122) or mock-transfected (CMV-S8) cells (Figure 3b ), a ®nding expected from the decrease in receptor autophosphorylation in the mutant receptor-expressing cells (Figure 2c ).
Wild-type PDGFa receptor expressing clones are highly metastatic
To test whether expression of wild-type PDGFa receptors confers upon the low-metastatic cells the ability to grow and colonize the lung parenchyma, transfectants, control clones (AP1 and AP3), and parental A9 and D122 cells were inoculated intravenously (experimental metastases) into syngeneic C57BL/6 mice ( Table 1A) . Survival of mice was followed for 93 days post-inoculation, after which mice that survived this period were sacri®ced. Autopsies of mice showed the presence of metastases only in the lungs. Lungs were removed and weighed as a measure of metastatic load. Mice inoculated with D122 cells survived an average of 40 days and all lungs contained heavy metastatic loads (Table 1A ; Immunocompetent). In contrast, mice inoculated with parental A9 or mock-transfected AP1 or AP3 cells were metastases-free and all mice in these groups survived the 93 day assay. Most lungs of mice inoculated with PDGFa receptor-transfected cells (AN20, AN22, AN23, AN23-1 and AN24) had many metastases and Table 1A ). Although most mice inoculated with transfected clones had metastases in the lungs, they survived longer than mice inoculated with the high metastatic D122 clone (Table 1A) . These results suggested there are additional mechanisms contributing to the control of metastatic spread. In our previous studies we have demonstrated that the low metastatic clone A9 expresses much higher levels of MHC class I H-2K b glycoproteins compared to the high metastatic clone D122, resulting in greater immunogenicity of the former (Eisenbach et al., 1984) . In fact, immunization of naive C57BL/6 mice with irradiated A9 cells partially retards the development of a subsequent A9 challenge, while immunization with irradiated D122 cells does not aect the growth of a second D122 tumor (Eisenbach et al., 1984) .
We speculated that the longer survival periods produced by A9-derived clones might be causally related to the higher immunogenicity of this parental clone. Therefore, we repeated the assay for experimental metastasis with sublethaly irradiated mice (Table 1A , Irradiated). This treatment partially inactivates immune responses in vivo. Again, mice were inoculated intravenously and followed for 93 days. Those that succumbed were autopsied, and their lungs removed and weighed. As in immunocompetent mice, PDGFa receptor transfectants were metastatic in irradiated mice, while control clones were non or low (clone AP3) metastatic. No statistically signi®cant dierences in lung weights were noted for any clone between irradiated and immunocompetent groups of mice. However, irradiated recipients inoculated with cells of all transfectants survived less time than immunocompetent mice inoculated with the same cells, con®rming a partial role for immune functions in the kinetics of metastases formation. Indeed, when levels of H-2K b cell surface antigens were examined by a direct radioimmunoassay, they were as high in transfectants as in parental A9 cells (data not shown). Thus, although immune mechanisms aect the survival of inoculated mice, the expression of PDGFa receptors clearly conferred on low-metastatic A9 cells the ability to proliferate extensively in the lungs.
We subsequently tested tumorigenicity and the capacity to generate spontaneous metastases by the PDGFa receptor transfected clones in immunocompetent and irradiated C57BL/6 recipients (Table 1B) . Following injection of 2610 5 cells per mouse in the right hind footpad, all clones were found to be tumorigenic at this dose and the growth rates of their local tumors were not distinctly dierent (data not shown). Actually, in some experiments the low-metastatic, PDGFa receptor negative A9 clone grew faster than the high-metastatic D122 clone in the footpad. This lack of correlation between metastatic phenotype and growth rates of local tumors was demonstrated before in a large group of 3LL clones (Eisenbach et al., 1984) .
When the size of individual local tumors reached 8 mm in diameter, the tumor bearing foot was surgically removed and survival was followed for 81 days. Lungs of mice that succumbed were removed and weighed. Table 1B summarizes the average survival times and lung weights of the mice in the various groups. All PDGFa receptor expressing transfectants were highly metastatic in the spontaneous assay in immunocompetent as well as irradiated recipients, and survival times were signi®cantly reduced (see P values, Table 1B ). Control receptor-negative groups, on the other hand, were either non or low metastatic. In irradiated mice inoculated with PDGFa receptor transfectants survival times were similar to that of highly metastatic D122 cells. However, survival of immunocompetent mice inoculated with transfectants was prolonged relative to mice carrying D122 tumors but was still much shorter than survival of receptornegative control groups, again con®rming a partial eect of the immune system. The group injected with AN20 cells survived the longest, indicating that this clone might be more immunogenic than other transfectants. Most control mice carrying A9, AP1 or AP3 tumors were sacri®ced at the end of the experiment without developing any metastases while few died earlier with isolated metastatic nodules.
Comparison of survival rates and metastatic loads among PDGFa receptor overexpressing clones showed that cell line AN23-1 was consistently the most malignant. This clone is the highest expressor of PDGFa receptors (Figure 1 ) and grows in vitro in response to PDGF-AA at a rate similar to high metastatic D122 cells (Figure 3 ). This indicates that selection in vivo for metastatic growth (from a metastatic nodule of clone AN23) is correlated with selection for high PDGFa receptor expression.
Truncated PDGFa receptor-expressing clones have reduced metastatic capabilities
Since the PDGF-induced autophosphorylation and growth of kinase mutant transfectants were reduced in comparison to parental high metastatic D122 cells (Figures 2c and 3b) we tested whether their metastatic capabilities were similarly altered. In the experimental metastases protocol, mice were sacri®ced 43 days post inoculation and metastatic load assessed (Figure 4, IV) . The lungs of control clones D122, CMV-S7 and CMV-S8 were highly metastatic with average lung weights of 736 ± 1290. Lungs of mice inoculated with kinase mutant expressing cells MD4, MD5 and MD10 were much less metastatic, almost reaching the normal lung weight of 200 mg. MD11, a clone which has undetectable truncated PDGFa receptor RNA expression (Figure 2a) , retained a phenotype similar to control highly metastatic cells.
Next we tested tumorigenicity and the ability of kinase mutant receptor expressing clones to produce metastases in a spontaneous assay by injecting 2610 5 cells in the right hind footpad. All clones were found to be tumorigenic at this dose and grew at similar rates once tumors were initiated. Interestingly, however, we noted a delay of 5 ± 10 days in the onset of local tumor growth produced by kinase mutant transfectants (data not shown). Once tumors reached a size of 8 mm they were removed and mice were sacri®ced 30 days later. As in the experimental protocol, lung weights of mice injected with kinase mutant transfectants were signi®cantly reduced when compared to control highly (Figure 4, IFP) . Again, the nonexpressor clone MD11 retained its metastatic phenotype. However, it is important to note that in a similar experiment, in which MD4, MD5 and MD10-injected mice were monitored for survival, all mice eventually developed metastases 60 ± 100 days post-amputation (data not shown). Thus the decrease in PDGFa receptor signaling reduces the rate of metastases formation by 3LL clones.
Discussion
For an intruding metastatic cell, the ability to grow in and respond to a target organ environment, in this case the lung, may be due to the aberrant expression of growth factor receptors. We previously showed the presence of functionally intact PDGFa receptors in highly metastatic clones of the 3LL Lewis lung carcinoma (Do et al., 1992; Fitzer-Attas et al., 1993) . A weakly metastatic clone of the same tumor had undetectable levels of this receptor and was, accordingly, nonresponsive to PDGF. We suggested then that the interaction of PDGF-like factors, demonstrated in lung conditioned media, with PDGF receptors on the metastatic tumor cell may be important in the development of metastatic lesions in this organ. In the present report, we have extended these studies by altering either the expression or function of PDGFa receptors in low or highly metastatic cells, respectively, and have shown dramatic eects of these modi®cations on metastatic phenotype.
The introduction of wild-type PDGFa receptors, as con®rmed by both Northern and Western analyses (Figure 1 ), consistently conferred high-metastatic competence on low-metastatic A9 cells, both in spontaneous and experimental metastases protocols (Table 1) . This newly acquired highly metastatic phenotype was not a result of an increased prolifera- For the experimental protocol (A), syngeneic C57BL/6 mice, immunocompetent or irradiated, were injected intravenously with indicated clones. Survival of mice was followed for 93 days post-inoculation. For the spontaneous protocol (B), immunocompetent or irradiated C57BL/6 mice were injected with 2610 5 cells in the hind footpad. When the diameter of local tumors reached 8 mm, the tumor bearing foot was surgically removed and survival was followed for 81 days. P values were calculated using Student's unpaired two-tail t test upon comparison to survival of low metastatic A9 cells. Upon death or termination of experiment, lungs were removed and weighed as a measure of metastatic load Figure 4 Truncated PDGFa receptor-expressing clones lose their metastatic capabilities. Syngeneic C57BL/6 mice were injected intravenously (IV) or intrafootpad (IFP) for experimental or spontaneous metastases protocols, respectively. In the experimental protocol, mice were sacri®ced 43 days post inoculation and lung weights determined. In the spontaneous protocol, mice were sacri®ced 30 days after removal of the tumor-bearing foot, and metastatic load assessed. D122, highly metastatic; CMV-S7, CMV-S8, mock transfectants; MD4, MD5, MD10 and MD11, truncated PDGFa receptor transfectants tion rate since in vitro, in the presence of serum, the A9 transfectants proliferate similarly to PDGFa receptor negative parental cells (data not shown). Moreover, receptor expression had no eect on the in vivo growth rates of local tumors in the footpad of syngeneic immunocompetent or irradiated recipients (not shown), indicating that other growth factors and their receptors may control local tumor growth. On the other hand, the wild-type PDGFa receptor transfectants were induced to proliferate in vitro in the presence of PDGF-AA (Figure 3) , con®rming the presence of functional cell-surface receptors. In fact, the one clone which was recultured from a metastatic lung nodule, AN23-1, was stimulated to grow in the presence of PDGF-AA at levels similar to high metastatic D122 cells. This same clone was not only the highest expressor of PDGFa receptors, but also the most malignant transfectant. These results indicate that selection in vivo for metastatic growth correlates well with high PDGFa receptor expression and responsiveness to PDGF ligand.
Expression of PDGF ligands and their receptors has been recently studied in a number of human tumors and hyperplastic tissues. Autocrine stimulation of tumor cell proliferation has been suggested in primary human astrocytomas (Maxwell et al., 1990b) , meningiomas (Maxwell et al., 1990a) , lung carcinomas (Antoniades et al., 1992) , and epithelial ovarian neoplasms (Henriksen et al., 1993) . A combination of autocrine and paracrine loops involving PDGF ligands and receptors was demonstrated in human glioblastomas (Hermanson et al., 1992) and AIDS-related Kaposi's sarcoma (Sturzl et al., 1992) . PDGF appears to have a paracrine eect on tumor stroma development in basal cell carcinoma (Ponten et al., 1994) and lung cancer (Vignaud et al., 1994) . Smits et al. (1992) demonstrated that, while PDGFb receptors are expressed in various proliferative disorders, PDGFa receptors are expressed only on fully malignant disorders of ®broblastic origin. Interestingly, both overexpression and a dierential processing of PDGFa receptors was recently shown to be involved in human metastatic colon cancer (Craven et al., 1995) . Collectively, these results demonstrate that PDGF, via both autocrine and paracrine modes of stimulation can contribute to tumorigenesis and malignancy of cells of various histological origins.
In our model system tumor cells of high or low metastatic phenotypes do not express mRNA of PDGF A and B chains and conditioned media from both cell lines do not stimulate autophosphorylation of PDGF receptors , suggesting that an autocrine mechanism of cell growth is not involved. We therefore postulate that a paracrine mechanism is involved in the formation of lung metastases via PDGFa receptor expressing cells. This notion would imply that lung tissue possess cells which synthesize and secrete locally high levels of PDGF. Our previous studies indeed demonstrated that conditioned media of lung, but not of liver or kidney tissues, preferentially stimulates the proliferation of high metastatic D122 cells and exhibits high levels of PDGF like factors .
In the developing lung, PDGF-A signaling was shown to have a role in epithelial-mesenchymal interactions during early lung branching morphogenesis (Souza et al., 1995) and to be crucial for alveolar myo®broblast ontogeny and alveogenesis (Bostrom et al., 1996) , while PDGF-B appears to be the mediator of fetal lung cell growth induced by mechanical strain such as fetal breathing . Other studies have shown that activated human alveolar macrophage secrete PDGFs Mornex et al., 1986; Shimokado et al., 1985) . Thus, postnatally, PDGF appears to be one of the factors available to the alveolar macrophage for mediating normal lung defense and lung in¯ammation . This may suggest that tumor cells invading the lung paranchyma activate resting alveolar macrophages (Van Furth, 1980) , inducing them to secrete PDGF ligands. These PDGF ligands can in turn stimulate the proliferation of certain invading tumor cells, those equipped with appropriate and functional PDGF receptors.
In the 3LL system, we have also reported that reduced expression of MHC class I antigens on the cell surface correlates with reduced immunogenicity and increased malignancy of tumor clones (Eisenbach et al., 1983) . The low metastatic clone A9, however, does express signi®cant levels of MHC class I molecules and is highly immunogenic, i.e. A9 cells induce anti-tumor cytotoxic T lymphocytes (CTL) that kill MHC class I expressing cells. Accordingly, although the PDGFa receptor A9 transfectants and D122 cells show similar metastatic loads, the survival time of mice injected with A9 transfectants is greater than the poorly immunogenic, highly metastatic clone D122 (Table 1) . Furthermore, in irradiated mice, where the immune system is partially inactivated, the rate of metastases formation was somewhat accelerated over immunocompetent recipients in mice injected with A9 transfectants, but not in mice injected with poorly immunogenic D122 cells. Collectively, these data con®rm a partial role for immune functions in control of the metastatic process, aecting survival time of inoculated mice. In fact, increasing the endogenous immunogenicity of D122 cells by transfection with H-2K b or MHC class I regulator genes, abrogates their metastatic phenotype by enabling the MHC expressing cells to induce an eective CTL response (Plaksin et al., 1988; Porgador et al., 1993; Yamit-Hezi et al., 1994 ). Yet, importantly, expression of wild-type PDGFa receptors in 3LL cells is a crucial factor in determining their ability to colonize and expand in the lung.
Transdominant negative mutations have recently been accepted as an eective means of disrupting growth factor-initiated signaling pathways (Shamah and Stiles, 1995) . For monomeric receptor tyrosine kinases, ligand-receptor interactions induce noncovalent dimerization of receptor chains, an event which is essential for activation of their kinase domains (Schlessinger and Ullrich, 1992) . Deletions of PDGFa or b receptor cytoplasmic domains or mutations in the ATP binding site have eectively yielded dominant negative mutants, by forming ligand-induced, nonfunctional oligomers with wild-type receptors (Kemp et al., 1993; Strawn et al., 1994; Ueno et al., 1991 Ueno et al., , 1993 . Such complexes were shown to be incapable of mediating early signaling events such as receptor autophosphorylation, PI3-kinase association and calcium mobilization (Ueno et al., 1991) . Furthermore, truncated PDGFb receptors were shown to inhibit the mitogenic response of rat aortic vascular smooth muscle cells to PDGF-BB (Kemp et al., 1993) and the growth and tumorigenicity of rat glioma cells (Strawn et al., 1994) .
Similarly, we set out to con®rm the importance of PDGF receptor activation in the colonization of lung tissue by 3LL tumor cells by introducing a truncated PDGFa receptor into highly metastatic cells (Figures  2a and b) , thus decreasing formation of active receptor dimers. Indeed we have demonstrated reduced autophosphorylation of the endogenous PDGFa receptor in these cells (Figure 2c ), correlating with a decreased rate of proliferation in the presence of PDGF-AA ( Figure  3b) . Importantly, the ability of 3LL clones containing a truncated PDGFa receptor to metastasize the lung was signi®cantly compromised in both experimental and spontaneous metastases assays (Figure 4) .
The ability of disseminating tumor cells to grow in a target organ is the ®nal limiting step of the metastatic cascade. The data we present here complement our earlier ®ndings correlating the presence of functionally intact PDGFa receptors in 3LL epithelial cells with lungcolonizing capability (Do et al., 1992; Fitzer-Attas et al., 1993) . First, we were able to demonstrate that the expression of functional PDGFa receptors in this tumor transforms cells from low to highly-metastasizing. Second, with the speci®c dominant-negative inhibition of PDGFa receptors in highly metastatic D122 cells we unequivocally showed the importance of PDGF signaling in the in vivo growth of metastatic 3LL tumor cells. The implication of PDGF signaling in malignant progression suggests that disruption of this pathway in certain cancer cells may be a viable strategy to block their ectopic growth in a target organ.
Materials and methods
Mice and cell culture C57BL/6 mice, 8 ± 12 weeks old, were obtained from the Jackson Laboratory (Ann Arbor, Maine). Cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% heat-inactivated fetal calf serum. Transfected cells were selected and maintained in geneticin (800 mg/ml for A9, 400 mg/ml for D122) containing medium. The cells were incubated at 5% CO 2 at 378C. The rabbit polyclonal antibody to the extracellular region of the PDGFa receptor (Ab 3980) was kindly provided by Dr Neill Giese (COR Therapeutics, So. San Francisco, CA).
Wild-type PDGFa plasmid and probe A 3.5 kbp HindIII ± MluI cDNA insert encoding the entire 1089 amino acids open reading frame of PDGFa receptor (Do et al., 1992) was ®lled in and cloned into a SmaI site of pSVL expression vector (Pharmacia, Uppsala) and named pSGRa. A 1.8 kbp HindIII ± BamHI cDNA insert from the extracellular, transmembrane, and part of the intracellular domain of PDGFa receptor was used as a probe for Northern blot analyses.
Site-directed mutagenesis
For template, the 1.8 kbp HindIII ± BamHI fragment of the PDGFa receptor was subcloned into Bluescript SK + and uracil-modi®ed single stranded DNA was prepared using CJ236 (dut 7 , ung 7 ) bacteria. A 27 bp oligonucleotide spanning positions 1822 ± 1848 of the PDGFa receptor cDNA, with a single nucleotide change (T to G) at position 1836 to convert a tyrosine residue to a stop codon, was used for synthesis of the mutated strand with T4 DNA polymerase. Mutated PDGFa receptor DNA was cloned into the HindIII ± XbaI sites of the Rc/CMV expression vector and named pCGRa-tk.
DNA transfection
Twenty mg of pSGRa plasmid and 2 mg of pSV2neo, which contains the gene encoding geneticin resistance, were transfected into 5610 5 A9 cells by the calcium phosphate method. For mock transfections, 20 mg of empty pSVL vector and 2 mg of pSV2neo were used. Similarly, 20 mg of pCGRa-tk or 20 mg Rc/CMV (empty vector) was transfected with 2 mg of pSV2neo into 5610 5 D122 cells by the same method.
Northern blot analysis
Total RNA was extracted using a modi®cation of the guanidine thiocyanate method. A 50 mg aliquot of RNA from each clone was used for analysis and the 1.8 kb HindIII ± BamHI cDNA sequence was used as a probe. Electrophoresis, Northern blotting, probe preparation, hybridization and washings were done as described elsewhere (Do et al., 1992) .
Immunoprecipitation and Western blot analysis
For Western blot analysis of the kinase-mutant and mock transfectants, subcon¯uent cells in 90 mm plates were washed with and scraped into 5 ml of PBS. Cells were solubilized in lysis buer A (1% NP-40, 1 mM PMSF, 5 mM iodoacetamide, 10 mg/ml aprotonin, 20 mg/ml leupeptin) for 20 min on ice and then centrifuged at 17 000 g for 15 min at 48C for collection of supernatants. Proteins were quantitated with the Biorad Protein Assay and 70 mg of total lysate protein, in nonreducing Laemmli sample buer, were separated by SDS ± PAGE. Proteins were then electrotransferred to nitrocellulose membranes and reacted with 1 mg/ml Ab 3980 (Hall et al., 1996) . Recognition of the primary antibody was performed with peroxidaselabeled protein A followed by enhanced chemiluminescence (ECL, Amersham, Buckinghamshire, UK).
For all other protein studies, subcon¯uent cells in 90 mm plates were washed in PBS and scraped into 1 ml of lysis buer B (50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, 1 mM NaF, 1 mM PMSF, 0.4% aprotinin (24.4 TIU/ml), 5 mg/ml leupeptin, 10 mg/ml soybean trypsin inhibitor). Lysates were left to solubilize on ice for 20 min and then centrifuged at 17 000 g for 15 min at 48C for collection of supernatants. For receptor autophosphorylation studies, cells were starved overnight in de®ned media (DCCM, Bet HaEmek, Israel), stimulated with 200 ng/ml PDGF-AA in DCCM and lysed as above in lysis buer B without NaF but containing 10 mM sodium pyrophosphate and 80 mM b-glycerophosphate disodium salt. Equivalent amounts of lysate protein were subjected to sequential immunoprecipitation, ®rst with nonimmune serum coupled to protein A sepharose and then with a rabbit polyclonal anti-PDGFa receptor peptide-speci®c antibody, coupled to protein A sepharose. R5 (Figure 1b ) was generated against a peptide corresponding to amino acids 759 ± 772 of the interkinase domain whereas R9 (Figure 2c and d) was made against a peptide corresponding to amino acids 993 ± 1008 of the C-terminal tail (Fitzer-Attas, 1993) . Immunoprecipitates were washed three times in wash buer (10 mM Tris, pH 7.5, 140 mM NaCl, 0.1% SDS, 1% NP-40, 10 mM EDTA, 2 mM EGTA, 1 mM PMSF, 0.4% aprotonin (24.4 TIU/ml), 5 mg/ml leupeptin, 10 mg/ml soybean trypsin inhibitor), resuspended in 16 reducing SDS sample buer and separated by SDS ± PAGE. Proteins were then transferred to nitrocellulose membranes and reacted with the R5 antibody or a monoclonal antiphosphotyrosine antibody 4G10 (Upstate Biotechnology, Lake Placid, NY). Recognition of the primary antibody was visualized with the ECL Western blotting detection system.
In vitro growth assays
Cultures were set up in 24-well plates at a density of 5610 3 cells/well. Initial plating was done in DMEM containing 10% FCS. Approximately 18 h post-plating, media was replaced with 1 ml of DCCM (Beit HaEmek, Israel), and cells were incubated for an additional 24 h. Media was then replaced again with DCCM containing the appropriate concentration of PDGF-AA (Reprotech, Rocky Hill, NJ). After a 3 ± 4 day growth period, the cells were quantitated using a modi®ed crystal violet staining procedure as described elsewhere .
Tumor development and metastatic assays
Partial immune suppression was achieved by irradiating C57BL/6 mice at 500 rad 24 h before inoculation. Experimental metastasis: Mice were inoculated intravenously with 5610 5 cell per mouse. Lung weights were recorded for mice which died before the termination of the experiment. Surviving mice were sacri®ced and their lungs weighed. Spontaneous metastasis: mice were inoculated in the right hand footpad with 2610 5 cells per mouse. Local tumors were measured with calipers. When individual tumors reached a diameter of 8 mm, tumor bearing legs were amputated as described before (Plaksin et al., 1988) . Mice were followed for the indicated number of days post amputation and lung weights were determined as before. Normal lung weight is *200 mg.
Statistical analysis
Dierences between control, the A9 parental line, the AP1 and AP3 mock transfected clones, and individual experimental groups were evaluated using the student's t-test, by the Statview program. Likewise, dierences between D122 and kinase mutant transfectants in the development of metastases were evaluated with a two-tailed student's t-test.
